GW Tests Cannabinoid Epilepsy Drug in Humans

GW Pharmaceuticals has begun testing a cannabinoid drug on patients with epilepsy in a Phase I trial after preclinical data showed that its drug GWP42006 showed fewer side effects than traditional antiepileptic drugs.
Pharma Times